Last updated: August 8, 2026
Alavert is a loratadine-based over-the-counter antihistamine brand with limited remaining exclusivity value. Its commercial opportunity is primarily in differentiated delivery formats, taste masking, pediatric usability, packaging, and private-label supply rather than active-ingredient exclusivity. The core loratadine market is mature, highly genericized, and regulated through the FDA’s OTC antihistamine framework rather than a conventional prescription-drug launch model.[1][2]
What is Alavert and how is it regulated?
Alavert contains loratadine, a second-generation H1 antihistamine used for temporary relief of allergy symptoms and hives. U.S. products have been marketed in tablet, orally disintegrating tablet, chewable, and liquid formats, depending on the specific product and manufacturer.
What is the FDA status of Alavert?
Alavert is an OTC drug product. Loratadine is recognized within the FDA framework for OTC antihistamine products, subject to applicable active-ingredient, dose, labeling, and safety conditions.[1]
Unlike a prescription product with a specific New Drug Application and Orange Book patent listings, Alavert’s commercial products operate within the OTC monograph system or an applicable OTC monograph order. The brand can have trademark and formulation value even when the active ingredient is widely available from generic manufacturers.
The principal regulatory requirements include:
- Loratadine dose and route consistent with FDA OTC conditions.
- Drug Facts labeling.
- Age-specific dosing and warnings.
- Appropriate excipient safety for the dosage form.
- Stability through the labeled shelf life.
- Compliance with current good manufacturing practice.
- Child-resistant packaging where required.
- Allergen, sweetener, and inactive-ingredient disclosure.
What excipients are used in Alavert formulations?
The excipient profile depends on the dosage form and product version. Alavert orally disintegrating products have historically used excipients such as mannitol, gelatin, citric acid, flavoring agents, and aspartame, although the precise composition must be confirmed against the current package label or DailyMed record for the specific National Drug Code.[3]
How do Alavert ODT excipients affect product performance?
An orally disintegrating loratadine tablet has four formulation priorities:
- Rapid breakup in the mouth.
- Acceptable taste without water.
- Adequate mechanical strength during handling.
- Protection against moisture during storage.
Mannitol is commercially useful in ODTs because it provides a cooling mouthfeel, relatively low hygroscopicity, and a smooth sensory profile. It can also function as a diluent and improve tablet bulk.
Gelatin can support rapid disintegration and mouthfeel but creates vegetarian, religious, allergen, and supply-chain constraints. A gelatin-free ODT could use crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, or a directly compressible mannitol system.
Citric acid contributes acidity and can modify flavor perception. It may also support a more acceptable taste profile when combined with sweeteners and flavors. Its level must be controlled because excessive acidity can reduce palatability and affect chemical stability.
Aspartame provides high-intensity sweetness at low use levels. It creates a labeling requirement for consumers with phenylketonuria and may reduce the addressable market among consumers seeking aspartame-free products. Sucralose, acesulfame potassium, steviol glycosides, or sugar alcohol systems could support alternative positioning, subject to taste, dose, and regulatory review.
What excipients are relevant to standard loratadine tablets?
Conventional tablets can use lactose, microcrystalline cellulose, starch, croscarmellose sodium, crospovidone, povidone, colloidal silicon dioxide, and magnesium stearate. The selection affects:
- Disintegration time.
- Tablet hardness.
- Friability.
- Powder flow.
- Lubrication.
- Dissolution.
- Compression throughput.
- Cost per dose.
Loratadine is a low-dose active ingredient, so content uniformity is a central manufacturing issue. Excipient selection must support uniform distribution of the active at a 10 mg dose. Segregation risk increases when particle size, density, or flow properties differ materially between loratadine and the principal diluent.
What excipient strategies create commercial opportunities for Alavert?
The strongest opportunities are formulation-led. They do not depend on extending loratadine’s basic patent life.
1. Aspartame-free orally disintegrating tablets
An aspartame-free Alavert-compatible ODT could target consumers avoiding phenylalanine labeling or artificial sweeteners. The development challenge is taste masking. Loratadine has an inherently difficult sensory profile, and a replacement sweetener must not create excessive cooling, bitterness, aftertaste, or hygroscopicity.
Potential systems include:
- Mannitol with sucralose.
- Mannitol and acesulfame potassium.
- Co-processed mannitol-based excipients.
- Steviol glycosides combined with flavor modulators.
- Ion-exchange resin taste masking.
- Polymer coating of loratadine particles.
The commercial value would depend on whether the product is positioned as a genuine consumer benefit rather than a minor ingredient change.
2. Gelatin-free ODTs
Replacing gelatin could expand the product’s suitability for vegetarian, vegan, kosher, halal, and selected international markets. A compressed ODT based on mannitol and a superdisintegrant may reduce animal-derived material and simplify global sourcing.
The main risks are tablet friability, poor mouthfeel, and moisture sensitivity. A lyophilized tablet can deliver rapid dispersion but usually has higher packaging and manufacturing costs than a compressed ODT.
3. Sugar-free chewable tablets
Chewables can improve adherence for children and adults who have difficulty swallowing. A sugar-free product based on xylitol, sorbitol, mannitol, or isomalt can support dental-health positioning, but polyol levels may cause gastrointestinal tolerance issues.
A chewable loratadine formulation requires stronger taste masking than a conventional swallowed tablet. Flavor selection is important because citrus, berry, and grape profiles interact differently with loratadine bitterness.
4. Pediatric liquid with improved preservative and flavor systems
Loratadine oral solution has a broader usability profile for younger children and consumers unable to swallow tablets. Commercial differentiation can come from:
- Preservative-free or reduced-preservative positioning where feasible.
- Dosing syringes rather than cups.
- Unit-dose packaging.
- Lower-sugar or sugar-free formulations.
- Improved flavor systems.
- Reduced staining and lower viscosity.
- Child-resistant but caregiver-friendly closures.
The liquid format creates greater microbiological, chemical-stability, and packaging complexity than solid dosage forms. Preservative selection must account for pH, container compatibility, flavor components, and microbial challenge performance.
5. Moisture-protective packaging
For ODT products, the package may be as important as the excipient system. Aluminum-aluminum blister packaging provides strong moisture protection but carries higher cost. High-barrier PVC or polymer blister structures may reduce cost but require validated moisture transmission performance.
Commercial options include:
- Single-dose blister packs.
- Calendarized allergy-season packaging.
- Portable pocket packs.
- Unit-dose formats for travel.
- Desiccant-containing bottles.
- Senior-friendly blister designs.
Packaging claims must be supported by stability data. A faster-disintegrating tablet that loses performance under humid storage has limited commercial value.
What patents protect Alavert and loratadine products?
The original loratadine composition-of-matter protection has expired. Loratadine was approved in the United States in 1993, and generic competition has existed for many years.[2][4]
When did loratadine lose exclusivity?
The principal commercial exclusivity period for loratadine ended around the turn of the century. The original Claritin-era patent estate no longer prevents generic loratadine tablets, chewables, liquids, or comparable products from entering the market.
The current protection profile is therefore based mainly on:
- Trademarks.
- Product-specific formulation patents, if any remain in force.
- Packaging and device rights.
- Trade secrets.
- Manufacturing know-how.
- Consumer brand recognition.
- Retail distribution agreements.
Patent protection for a new loratadine excipient system would need to claim more than routine substitution of one diluent or sweetener for another. A defensible formulation patent would typically require a specific combination of composition, performance, and measurable technical effect, such as improved stability, reduced bitterness, rapid disintegration under defined conditions, or enhanced bioavailability.
Does Alavert have Orange Book-listed patents?
Alavert is an OTC loratadine product, not a conventional prescription drug with a standard Orange Book patent listing structure. The absence of an Orange Book listing does not eliminate all intellectual-property rights, but it means that the principal generic-entry analysis is not based on an Orange Book Paragraph IV certification.
For a new prescription product, Paragraph IV litigation could delay approval or produce a 30-month stay in certain circumstances. That pathway is generally not the central barrier for established OTC loratadine products marketed under the FDA’s OTC framework.[1][5]
Are biosimilar risks relevant to Alavert?
No. Alavert contains loratadine, a chemically synthesized small molecule. Biosimilar competition applies to biological products, not conventional small-molecule antihistamines. The relevant competitive threats are:
- Authorized generics.
- Store-brand loratadine.
- National generic manufacturers.
- Private-label retailers.
- Combination allergy products.
- Competing antihistamines such as cetirizine, fexofenadine, and desloratadine.
Which companies challenge Alavert commercially?
The competitive field includes large generic manufacturers, OTC marketers, pharmacy chains, mass retailers, and private-label suppliers. Products are commonly sold under names such as generic loratadine, store-brand allergy relief, Claritin, and other retailer-controlled brands.
The strongest competitive pressure comes from price parity and shelf placement. Since the active ingredient is mature and widely sourced, differentiation depends on:
- Retail price.
- Tablet count.
- Dosage form.
- Consumer trust.
- Seasonal promotion.
- Package convenience.
- Pediatric appeal.
- Availability during peak allergy periods.
How does Alavert compare with competing antihistamines?
| Product |
Active ingredient |
Typical differentiation |
Excipient opportunity |
Competitive risk |
| Alavert |
Loratadine |
Non-drowsy allergy relief; ODT and chewable formats |
Taste masking, sugar-free ODT, gelatin-free systems |
High generic and private-label pressure |
| Claritin |
Loratadine |
Established national brand |
Brand-specific delivery formats |
High, but stronger brand recognition |
| Zyrtec |
Cetirizine |
Strong efficacy perception; some drowsiness concern |
Chewables, liquids, flavor systems |
High category competition |
| Allegra |
Fexofenadine |
Non-drowsy positioning |
ODT, suspension, pediatric products |
High national-brand competition |
| Generic loratadine |
Loratadine |
Low price |
Basic tablet and liquid manufacturing |
Very high price pressure |
Loratadine’s main commercial advantage is its established non-drowsy positioning. Its weakness is the limited ability to command a premium over generic equivalents without a clear dosage-form or consumer-experience benefit.
What manufacturing and intellectual-property barriers affect new Alavert products?
The principal barriers are technical and commercial rather than active-ingredient patent barriers.
Manufacturing barriers
ODT and chewable products require control of:
- Content uniformity.
- Blend segregation.
- Tablet tensile strength.
- Friability.
- Disintegration.
- Moisture uptake.
- Flavor uniformity.
- Packaging seal integrity.
Liquid products require control of:
- Microbial quality.
- Preservative effectiveness.
- pH.
- Sedimentation or crystallization.
- Container compatibility.
- Dose-measuring accuracy.
Intellectual-property barriers
A new entrant should assess:
- Active and inactive ingredient claims.
- ODT architecture.
- Taste-masking technology.
- Film coatings.
- Multiparticulate systems.
- Child-resistant closures.
- Proprietary blister structures.
- Trademarks and trade dress.
- Supplier exclusivity.
- Manufacturing process know-how.
The most defensible formulation estate would combine composition claims with process and performance claims. A broad claim to “loratadine plus mannitol” would likely face substantial validity and obviousness pressure because those materials are widely used in oral solid dosage forms.
What is the revenue exposure and commercial outlook for Alavert?
Alavert’s revenue is not generally reported as a separately disclosed material business line in major-company financial reporting. The brand’s economic value is therefore difficult to isolate from broader OTC or consumer-health portfolios.
The commercial outlook is strongest for products that improve convenience or tolerability:
- Aspartame-free ODT.
- Gelatin-free fast-dissolving tablet.
- Sugar-free chewable.
- Pediatric liquid with dosing syringe.
- Unit-dose travel packaging.
- Retailer-exclusive seasonal packs.
- Private-label supply with differentiated excipient specifications.
A basic loratadine tablet has low strategic value because multiple manufacturers can supply equivalent products. A differentiated formulation can support better margins, but the premium must exceed the cost of taste masking, specialized excipients, stability testing, and higher-barrier packaging.
What is the likely generic launch scenario for a new Alavert formulation?
A conventional loratadine tablet faces immediate generic substitution risk. A new dosage form can reduce direct substitution if it has:
- A distinct NDC.
- Strong consumer-facing differentiation.
- Reliable retail distribution.
- Meaningful formulation claims.
- Acceptable pricing.
- A package format that retailers cannot easily replicate.
The most likely launch model is not a Paragraph IV challenge. It is an OTC reformulation or private-label development program using loratadine API from multiple qualified suppliers. The commercial winner is likely to be the manufacturer that combines low conversion cost with consistent taste, rapid disintegration, and reliable seasonal supply.
Key takeaways
- Alavert is a loratadine OTC brand with limited active-ingredient exclusivity.
- The original loratadine patent estate is expired, and generic competition is entrenched.
- Orange Book and Paragraph IV mechanisms are not the primary commercial barriers for established OTC loratadine products.
- Excipient differentiation is most valuable in ODTs, chewables, liquids, taste masking, and moisture protection.
- Aspartame-free, gelatin-free, sugar-free, and pediatric-friendly formats have the clearest product-development rationale.
- Biosimilar risk is irrelevant because loratadine is a small molecule.
- The strongest IP position would require a non-obvious excipient combination with demonstrated technical performance.
- Revenue exposure is likely modest relative to larger consumer-health brands and is not generally separately disclosed.
- Private-label, retailer-exclusive, and seasonal packaging programs may offer better near-term returns than a basic branded tablet launch.
FAQs
Can mannitol replace gelatin in an Alavert ODT?
Mannitol can replace part of the functional role of gelatin as a diluent and mouthfeel agent, but it does not replicate every manufacturing property of a gelatin-based ODT. A gelatin-free formulation would normally require optimization of binder, superdisintegrant, compression force, hardness, friability, and moisture protection.
Is loratadine still protected by a composition-of-matter patent?
No. The original loratadine composition-of-matter protection expired years ago. Current commercial barriers are mainly brand, formulation, packaging, manufacturing, and retail-distribution rights.
What is the best excipient for masking loratadine bitterness?
No single excipient is universally optimal. A high-performing system commonly combines a low-hygroscopic diluent such as mannitol with high-intensity sweetener, flavor, acidulant, and, where required, a particle-coating or resin-based taste-masking technology.
Can a new Alavert product obtain pediatric exclusivity?
A new OTC formulation does not automatically receive pediatric exclusivity. Pediatric regulatory incentives depend on the applicable FDA pathway and agency request. A product aimed at children must still satisfy age-specific labeling, safety, dosing, and excipient requirements.
Does a novel Alavert excipient combination create freedom-to-operate risk?
Yes. Even with expired loratadine compound protection, a new product can implicate active formulation patents, taste-masking patents, ODT manufacturing patents, packaging rights, trademarks, and trade dress. Freedom-to-operate analysis must be product-specific and jurisdiction-specific.
References
-
U.S. Food and Drug Administration. (2024). OTC Monograph M012: Antihistamine drug products for over-the-counter human use. FDA.
-
U.S. Food and Drug Administration. (1993). Claritin (loratadine) approval history and labeling. FDA Drugs@FDA.
-
National Library of Medicine. (2024). DailyMed: Alavert loratadine product labeling. U.S. National Library of Medicine.
-
U.S. Patent and Trademark Office. (1981). U.S. Patent No. 4,282,233: Piperidine derivatives. USPTO.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
